GlassScriptPhysician profile
Christopher J Whiting
NPI 1104168533
$12,203.42
in general payments reported to CMS, 2019-2025
16 companies · $988 in 2025
The $988 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2021: $249 · 2022: $170 · 2023: $6,648 · 2024: $3,713 · 2025: $988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,950 · Consulting Fee: $2,250 · Food and Beverage: $2,115 · Travel and Lodging: $2,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,950.00 |
| Consulting Fee | $2,250.00 |
| Food and Beverage | $2,115.12 |
| Travel and Lodging | $2,034.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $6,719.38 | 2022-2023 | Uplizna |
| Amgen INC. | $3,801.25 | 2024-2025 | Uplizna, Tepezza |
| Alexion Pharmaceuticals, INC. | $668.94 | 2019-2024 | Soliris, Ultomiris |
| Emd Serono, INC. | $230.21 | 2019 | |
| Novartis Pharmaceuticals Corporation | $145.67 | 2019 | |
| Ucb, INC. | $137.18 | 2025 | Rystiggo, Nayzilam, Fintepla |
| Genzyme Corporation | $99.23 | 2022 | |
| Jazz Pharmaceuticals INC. | $91.67 | 2025 | |
| Tg Therapeutics, INC. | $66.43 | 2025 | |
| Neurocrine Biosciences, INC. | $64.23 | 2025 | |
| Neurelis, INC. | $40.00 | 2025 | Valtoco |
| Abbvie INC. | $34.54 | 2025 | |
| Tanabe Pharma America, INC. | $32.49 | 2025 | Radicava |
| Aucta Pharmaceuticals, INC. | $30.49 | 2025 | Motpoly Xr |
| Grifols USA, LLC | $25.11 | 2025 | Gamunex-C |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $16.60 | 2025 | Crexont |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Whiting listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.